1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H -Preparation of ethyl pyrazolo[3,4-C]pyridine-3-carboxylate_Kain Industrial Additive
Background and overview[1] 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetra Hydro-1H-pyrazolo[3,4-C]pyridine-3-carboxylic acid ethyl ester is an intermediate for the preparation of apixaban, an antithrombotic drug produced by Bristol-Myers Squibb in the United States. -The factor Xa direct inhibitor jointly developed by Bristol-Myers Squibb and Pfizer was approved for marketing in the EU in March 2011, and the FDA approved the drug for marketing in the United States in December 2012. Preparation[1] 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetra…
